- Home
- NVS vs WFC Comparison
NVS vs WFC Comparison
Compare NVS & WFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NVS | WFC |
|---|---|---|
| Founded | 1895 | 1852 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 261.7B | 261.7B |
| IPO Year | 2001 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NVS | WFC |
|---|---|---|
| Price | $141.00 | $80.03 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 26 |
| Target Price | ★ $156.29 | $100.54 |
| AVG Volume (30 Days) | 2.2M | ★ 8.9M |
| Earning Date | 10-27-2026 | 10-13-2026 |
| Dividend Yield | 2.16% | ★ 2.50% |
| EPS Growth | N/A | ★ 16.57 |
| EPS | N/A | ★ 3.60 |
| Revenue | N/A | ★ $85,063,000,000.00 |
| Revenue This Year | $1.88 | $6.08 |
| Revenue Next Year | $6.33 | $4.60 |
| P/E Ratio | $23.13 | ★ $22.29 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $121.57 | $72.78 |
| 52 Week High | $170.46 | $97.76 |
Technical Indicators
Market Signals| Indicator | NVS | WFC |
|---|---|---|
| Relative Strength Index (RSI) | 42.45 | 31.74 |
| Support Level | $136.28 | $79.25 |
| Resistance Level | $146.35 | $82.66 |
| Average True Range (ATR) | 1.84 | 2.02 |
| MACD | 0.59 | -0.76 |
| Stochastic Oscillator | 48.91 | 8.10 |
Price Performance
Historical ComparisonAbout NVS Novartis AG
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
About WFC Wells Fargo & Company
Wells Fargo is a premier, North American-focused banking titan that commands a $2.2 trillion balance sheet and the third-highest deposit market share in the United States. The bank uses a dense, expansive network of 4,093 branches to champion retail consumers and the middle market, where the firm has built a particularly strong reputation. Following the removal of its federal asset cap in 2025, the firm is set to deploy its legacy excess liquidity to expand each of its four segments: consumer & business lending, commercial banking, corporate & investment banking, and wealth & investment management.